Search results
Showing 101 to 150 of 163 results for metastatic breast cancer
Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery
Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)
Summary of the evidence on subcutaneous trastuzumab for HER2-positive breast cancer to inform local NHS planning and decision-making
Irreversible electroporation for treating primary lung cancer and metastases in the lung (IPG441)
Evidence-based recommendations on irreversible electroporation for treating primary lung cancer and metastases in the lung. This involves using electrical pulses to kill cancer cells.
View recommendations for IPG441Show all sections
Sections for IPG441
Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours
Uptake of NICE-approved medicines on the NHS to treat cardiovascular disease, diabetes and osteoporosis is higher than expected, latest figures reveal.
Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver
Evidence-based recommendations on bevacizumab (Avastin), with capecitabine, for treating metastatic breast cancer in adults.
Evidence-based recommendations on lapatinib (Tyverb) and trastuzumab (Herceptin) for treating metastatic hormone receptor-positive breast cancer that overexpresses HER2 in adults.
Eribulin for the treatment of locally advanced or metastatic breast cancer (TA250)
This guidance has been updated and replaced by NICE technology appraisal guidance 423 and NICE technology appraisal guidance 515.
Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)
Evidence-based recommendations on fulvestrant (Faslodex), for treating locally advanced or metastatic breast cancer in adults.
Evidence-based recommendations on bevacizumab (Avastin), with a taxane, for treating metastatic breast cancer in adults.
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)
Evidence-based recommendations on trastuzumab (Herceptin) for treating HER2-positive metastatic gastric cancer in adults.
Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)
Evidence-based recommendations on topotecan for treating recurrent and stage IVB cervical cancer in adults.
Image-guided radiofrequency excision biopsy of breast lesions (IPG308)
Evidence-based recommendations on image-guided radiofrequency excision biopsy of breast lesions. This involves inserting a probe that uses radiofrequency energy to cut through the breast internally, and removing the lump with a small area of surrounding tissue to test for cancer.
View recommendations for IPG308Show all sections
Sections for IPG308
Endoscopic mastectomy and endoscopic wide local excision for breast cancer (IPG296)
Evidence-based recommendations on endoscopic mastectomy and endoscopic wide local excision for breast cancer. This involves removing part or all of the breast using special instruments inserted through small cuts in the skin (keyhole surgery).
View recommendations for IPG296Show all sections
Sections for IPG296
Evidence-based recommendations on brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision. This involves inserting radioactive sources into the space in the breast where tissue has been removed to minimise the chances of the cancer coming back.
View recommendations for IPG268Show all sections
Sections for IPG268
Bevacizumab for the first-line treatment of metastatic breast cancer (TA147)
This appraisal has been updated and replaced by NICE technology appraisal 214.
Gemcitabine for the treatment of metastatic breast cancer (TA116)
Evidence-based recommendations on gemcitabine for treating metastatic breast cancer in adults.
Endoscopic axillary lymph node retrieval for breast cancer (IPG147)
Evidence-based recommendations on endoscopic axillary lymph node retrieval for breast cancer. This involves using narrow instruments to remove the lymph nodes through small, rather than large, openings to reduce the risk of infection and other problems.
View recommendations for IPG147Show all sections
Evidence-based recommendations on interstitial laser therapy for breast cancer. This involves using laser energy to destroying the cancer cells.
View recommendations for IPG89Show all sections
This appraisal has been updated and replaced by NICE guideline CG81.
Guidance on the use of vinorelbine for the treatment of advanced breast cancer (TA54)
This guidance has been updated and replaced by NICE guideline CG81.
This guideline covers how healthcare services for breast cancer should be organised. It aims to improve care for women with breast cancer by recommending which healthcare professionals should be involved in care.
Guidance on the use of trastuzumab for the treatment of advanced breast cancer (TA34)
Evidence-based recommendations on trastuzumab for treating advanced breast cancer in adults.
This webpage covers NICE guidelines on breast cancer. The table below presents the guidelines alphabetically with links to...
Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]
Discontinued [GID-TAG411]
Etirinotecan pegol for treating breast cancer with brain metastases [ID881]
Discontinued [GID-TA10066]
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]
In development [GID-TA11022] Expected publication date: TBC
In development [GID-TA10919] Expected publication date: TBC
Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]
Discontinued [GID-TAG417]
Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]
Discontinued [GID-TA10570]
Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]
Discontinued [GID-TAG403]
Awaiting development [GID-TA11110] Expected publication date: TBC
Awaiting development [GID-TA10960] Expected publication date: TBC
In development [GID-TA11318] Expected publication date: TBC
Awaiting development [GID-TA11339] Expected publication date: TBC
In development [GID-TA10261] Expected publication date: TBC
Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]
Discontinued [GID-TA10295]
In development [GID-TA11402] Expected publication date: TBC
In development [GID-TA11400] Expected publication date: TBC
Awaiting development [GID-TA11273] Expected publication date: TBC
Awaiting development [GID-TA11342] Expected publication date: TBC
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]
Awaiting development [GID-TA11411] Expected publication date: TBC